Announced
Completed
Financials
Tags
Domestic
Majority
Acquisition
Friendly
Biotechnology
Public
Single Bidder
biotech
United States
Completed
Synopsis
Endo Pharmaceuticals, a specialty pharmaceutical company, completed the acquisition of BioSpecifics, a commercial-stage biopharmaceutical company, for $658m. "BioSpecifics Technologies pioneered the development of collagenase-based therapies, which has resulted in a robust injectable collagenase portfolio, consisting of XIAFLEX to treat the vast number of diseases and medical conditions caused by the excess accumulation of collagen and Qwo for the treatment of cellulite," Joseph Truitt, BioSpecifics Chief Executive Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.